Literature DB >> 31650864

Integrated analysis of transcriptome-wide m6A methylome of osteosarcoma stem cells enriched by chemotherapy.

Yongjie Wang1, Lin Zeng2, Chao Liang1, Rui Zan3, Weiping Ji1, Zhichang Zhang1, Yuxuan Wei1, Shikui Tu4, Yang Dong1.   

Abstract

Aim: To analyze the m6A methylome of osteosarcoma stem cells (OSCs). Materials & methods: Chemoresistant OSCs were enriched by doxorubicin treatment. Expression of m6A-related enzymes was detected by quantitative real-time-PCR and western blot. MeRIP-seq and RNA-seq were performed to identify differences in m6A methylation and gene expression. Data analysis was conducted to explore the modified genes and their clinical significance.
Results: Three m6A-related enzymes were altered in OSCs. Differentially methylated genes were enriched in some pathways regulating pluripotency of stem cells. The expression of several candidate genes were found consistent with that in GSE33458 dataset, and associated with poor prognosis in osteosarcoma patients.
Conclusion: m6A may play a role in the emergence and maintaining of OSCs and affect the prognosis.

Entities:  

Keywords:  N6.methyladenosine (m6A) ; cancer stem cell; osteosarcoma

Mesh:

Substances:

Year:  2019        PMID: 31650864     DOI: 10.2217/epi-2019-0262

Source DB:  PubMed          Journal:  Epigenomics        ISSN: 1750-192X            Impact factor:   4.778


  25 in total

Review 1.  Structural biology of DNA abasic site protection by SRAP proteins.

Authors:  Katherine M Amidon; Brandt F Eichman
Journal:  DNA Repair (Amst)       Date:  2020-06-29

Review 2.  RNA N6-methyladenosine modification in regulating cancer stem cells and tumor immune microenvironment and its implication for cancer therapy.

Authors:  Subhadra Kumari; Santosh Kumar; Srinivasan Muthuswamy
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-07       Impact factor: 4.553

Review 3.  Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Authors:  Sruthi Sritharan; Sampurna Guha; Snoopy Hazarika; Nageswaran Sivalingam
Journal:  Apoptosis       Date:  2022-06-18       Impact factor: 5.561

4.  Comprehensive Analysis of Regulatory Networks of m6A Regulators and Reveals Prognosis Biomarkers in Sarcoma.

Authors:  Boran Pang; Dinghao Luo; Bojun Cao; Wen Wu; Lei Wang; Yongqiang Hao
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 5.  Regulatory Role of N6-Methyladenosine (m6A) Modification in Osteoarthritis.

Authors:  Ganggang Zhai; Likang Xiao; Chenyang Jiang; Songkai Yue; Meng Zhang; Jia Zheng; Zeming Liu; Yonghui Dong
Journal:  Front Cell Dev Biol       Date:  2022-06-30

6.  M6A demethylase FTO-mediated downregulation of DACT1 mRNA stability promotes Wnt signaling to facilitate osteosarcoma progression.

Authors:  Dongming Lv; Shirong Ding; Li Zhong; Jian Tu; Hongbo Li; Hao Yao; Yutong Zou; Ziliang Zeng; Yan Liao; Xuesi Wan; Lili Wen; Xianbiao Xie
Journal:  Oncogene       Date:  2022-02-04       Impact factor: 8.756

7.  m6A regulators are associated with osteosarcoma metastasis and have prognostic significance: A study based on public databases.

Authors:  Wenpeng Zhang; Lina Wang; Ping Zhang; Quanbin Zhang
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

Review 8.  Regulation of RNA N6-methyladenosine modification and its emerging roles in skeletal muscle development.

Authors:  Jiju Li; Yangli Pei; Rong Zhou; Zhonglin Tang; Yalan Yang
Journal:  Int J Biol Sci       Date:  2021-04-12       Impact factor: 6.580

9.  N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.

Authors:  Kun Yang; Fengyan Wang; Ke Li; Guoxuan Peng; Hua Yang; Hong Xu; Yang Xiang; Hong Sun
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 10.  Regulatory Role of N6-methyladenosine (m6A) Modification in Osteosarcoma.

Authors:  Yujie Zhang; Yanyan Wang; Liwei Ying; Sifeng Tao; Mingmin Shi; Peng Lin; Yangxin Wang; Bin Han
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.